Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, announced that preclinical data of its hepcidin induction program will be presented at the upcoming European Hematology Association 2021 Virtual Congress, which will be held from June 9-17.
CAMBRIDGE, Mass., May 24, 2021 /PRNewswire/ -- Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that preclinical data of its hepcidin induction program will be presented at the upcoming European Hematology Association (EHA) 2021 Virtual Congress, which will be held from June 9-17.
Details of the presentations are as follows:
Abstract Number: EP841
Title: DISC-B, a selective matriptase-2 inhibitor, elicited robust increase in hepcidin-25 and reduction in serum iron in cynomolgus monkeys
Session: Iron metabolism, deficiency and overload
The e-poster presentation will be made available as of Friday, June 11, 2021 (09:00 CEST) and will be accessible for on-demand viewing until August 15, 2021. The abstract is currently available online on EHA2021 Virtual Congress Platform.
About Disc Medicine
Disc Medicine is a biopharmaceutical company dedicated to transforming the lives of patients with hematologic disorders. We are building a unique portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology. We are committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic diseases. For more information, please visit www.discmedicine.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/disc-medicine-to-present-at-the-european-hematology-association-eha-2021-virtual-congress-301297069.html
SOURCE Disc Medicine
